These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 14023288)

  • 1. The treatment of cancer with large single doses of cytostatics under the protection of autologous bone marrow administration.
    COSTACHEL C; DRAGANESCU IC; DEMETRIU F
    Rum Med Rev; 1962; 6(3)():77-86. PubMed ID: 14023288
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intra-arterial administration of large doses of cytostatics under the protection of bone marrow transplantation in far-advanced cases of cancer].
    KOSTEKEL DO; DREGENESCU FI; MOGOS ; DEMETRIUM F
    Vopr Onkol; 1963; 9(2)():53-60. PubMed ID: 14035025
    [No Abstract]   [Full Text] [Related]  

  • 3. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate.
    Das JR; Fryar EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2006; 26(6B):4279-86. PubMed ID: 17201145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice.
    Wietrzyk J; Nevozhay D; Filip B; Milczarek M; Kutner A
    Anticancer Res; 2007; 27(5A):3387-98. PubMed ID: 17970085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.
    Pahlka RB; Sonnad JR
    Health Phys; 2006 Sep; 91(3):227-37. PubMed ID: 16891898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy.
    Ledzewicz U; Schättler H
    Math Biosci; 2007 Apr; 206(2):320-42. PubMed ID: 16197967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antiproliferation in prostate cancer cell lines with cytostatics and combinations with resistance modifiers.
    Pintér O; Mucsi I; Molnár J
    In Vivo; 2005; 19(1):253-9. PubMed ID: 15796183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Miltefosine decreases the cytotoxic effect of epirubicine and cyclophosphamide on mouse spermatogenic, thymic and bone marrow cells.
    Martinova Y; Topashka-Ancheva M; Konstantinov S; Petkova S; Karaivanova M; Berger M
    Arch Toxicol; 2006 Jan; 80(1):27-33. PubMed ID: 16079990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
    Montague R; Hart CA; George NJ; Ramani VA; Brown MD; Clarke NW
    Eur Urol; 2004 Sep; 46(3):389-401; discussion 401-2. PubMed ID: 15306113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection.
    Davis JH; Desoto JA; Fryar EB; Southerland WM; Bowen D
    Cell Mol Biol (Noisy-le-grand); 2007 May; 53(3):18-26. PubMed ID: 17531145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of cancer with high-dose chemotherapy and autologous stem cell transplantation].
    Geisler CH; Daugaard KG; Dickmeiss E; Ifversen M; Knudsen LM
    Ugeskr Laeger; 2003 Dec; 165(50):4846-9. PubMed ID: 14716902
    [No Abstract]   [Full Text] [Related]  

  • 12. Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane.
    Attia SM; Al-Anteet AA; Al-Rasheed NM; Alhaider AA; Al-Harbi MM
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):837-45. PubMed ID: 19184016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes and their regression in the osseous system in rats after administering a cytostatic drug inhibiting tumor cell division in the phase of DNA synthesis.
    Cegieła U; Pytlik M; Janiec W
    Pol J Pharmacol; 2004; 56(6):805-16. PubMed ID: 15662094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
    Gnant M; Dubsky P; Fitzal F; Blaha P; Schoppmann S; Steger G; Marth C; Samonigg H; Hüttner K; Fohler H; Ruecklinger E; Jakesz R; Greil R;
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S18-27. PubMed ID: 19561003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The place for therapeutic intensification in small cell lung cancer].
    Corne F; Thiberville L
    Rev Pneumol Clin; 2004 Nov; 60(5 Pt 2):3S104-9. PubMed ID: 15536362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients.
    Fujisaka Y; Tamura T; Ohe Y; Kunitoh H; Sekine I; Yamamoto N; Nokihara H; Horiike A; Kodama T; Saijo N
    Jpn J Clin Oncol; 2006 Aug; 36(8):477-82. PubMed ID: 16901911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salubrious effects of lipoic acid against adriamycin-induced clastogenesis and apoptosis in Wistar rat bone marrow cells.
    Prahalathan C; Selvakumar E; Varalakshmi P; Kumarasamy P; Saravanan R
    Toxicology; 2006 May; 222(3):225-32. PubMed ID: 16580770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate.
    Das JR; Fryar EB; Epie NN; Southerland WM; Bowen D
    Anticancer Res; 2006; 26(3A):1877-83. PubMed ID: 16827120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
    Martín A; Pérez-Simón JA; Caballero MD; López-Holgado N; Vázquez L; del Cañizo MC; San Miguel JF
    Haematologica; 2005 Jan; 90(1):78-85. PubMed ID: 15642673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.